Evidence map›Paper›PMID 25256151›Full record

ArticleJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2014

Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) study.

Behzad Hajarizadeh, Bart Grady, Kimberly Page, Arthur Y Kim, Barbara H McGovern, Andrea L Cox, Thomas M Rice, Rachel Sacks-Davis, Julie Bruneau, Meghan Morris and 11 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 10 institutions in 4 countries.

Behzad HajarizadehThe Kirby Institute, UNSW Australia, Sydney, NSW, Australia. Electronic address: bhajarizadeh@kirby.unsw.edu.au.
Bart GradyCluster Infectious Diseases, GGD Public Health Service of Amsterdam, Amsterdam, The Netherlands.
Kimberly PageDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
Arthur Y KimHarvard Medical School, Boston, MA, USA.
Barbara H McGovernTufts Medical School, Boston, MA, USA; Abbvie, Chicago, IL, USA.
Andrea L CoxDepartment of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Thomas M RiceDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
Rachel Sacks-DavisBurnet Institute, Melbourne, VIC, Australia; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Julie BruneauCRCHUM, Université de Montréal, Montreal, QC, Canada.
Meghan MorrisDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
Janaki AminThe Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
Janke SchinkelAcademic Medical Center, Amsterdam, The Netherlands.
Tanya ApplegateThe Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
Lisa MaherThe Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
Margaret HellardBurnet Institute, Melbourne, VIC, Australia; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Andrew R LloydInflammation and Infection Research Centre, School of Medical Sciences, UNSW Australia, Sydney, NSW, Australia.
Maria PrinsCluster Infectious Diseases, GGD Public Health Service of Amsterdam, Amsterdam, The Netherlands; Academic Medical Center, Amsterdam, The Netherlands.
Ronald B GeskusCluster Infectious Diseases, GGD Public Health Service of Amsterdam, Amsterdam, The Netherlands; Academic Medical Center, Amsterdam, The Netherlands.
Gregory J DoreThe Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
Jason GrebelyThe Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
InC(3)Study Group
Academic Medical Center · NLUniversity of California, San Francisco · USBurnet Institute · AUGGD Amsterdam · NLHarvard University · USJohns Hopkins University · USMonash University · AUTufts Medical Center · USUniversité de Montréal · CAUNSW Sydney · AU

Funding

UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Holger Willenbring · 1986 to 2026
$30.7M
Scientific CoreU19AI088791 · NIAID · JOHNS HOPKINS UNIVERSITY · PI COX, ANDREA L · 2010 to 2020
$8.2M
International Collaborative of prospective studies of HIV and Hepatitis in IDUR01DA031056 · NIDA · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI PAGE, KIMBERLY · 2011 to 2015
$2.2M
NIAID NIH HHS U19 AI088791NIDA NIH HHS R01 DA031056NIDA NIH HHS R01DA031056NIDDK NIH HHS P30 DK026743
6 · The paper itself

Abstract

BACKGROUND AND

objectivesHepatitis C virus (HCV) RNA level in acute HCV infection is predictive of spontaneous clearance. This study assessed factors associated with HCV RNA levels during early acute infection among people who inject drugs with well-defined acute HCV infection. STUDY

designData were from International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC(3)) Study, an international collaboration of nine prospective cohorts studying acute HCV infection. Individuals with available HCV RNA levels during early acute infection (first two months following infection) were included. The distribution of HCV RNA levels during early acute infection were compared by selected host and virological factors.

resultsA total of 195 individuals were included. Median HCV RNA levels were significantly higher among individuals with interferon lambda 3 (IFNL3, formerly called IL28B) CC genotype compared to those with TT/CT genotype (6.28 vs. 5.39logIU/mL, respectively; P=0.01). IFNL3 CC genotype was also associated with top tertile HCV RNA levels (≥6.3log IU/mL; vs. TT/CT genotype; adjusted Odds Ratio: 4.28; 95%CI: 2.01, 9.10; P<0.01).

conclusionsThis study indicates that IFNL3 CC genotype predicts higher HCV RNA levels in early acute HCV infection.

Indexed as

Viral LoadAdultCohort StudiesFemaleGenotypeHepacivirusHepatitis CHumansInterferon LambdaInterferonsInterleukinsMaleRNA, ViralSubstance Abuse, IntravenousYoung AdultInterferon Lambdainterferon-lambda, humanInterferonsInterleukinsRNA, ViralAcute HCVCohort studyIFNL3 genotypeIL28B genotypeViral load

Identifiers

PMID25256151
PMCPMC4279031
OpenAlexW2111226841

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.